-

Valerio Therapeutics: Postponement of 2024 Annual Financial Report Publication and the Approval of Financial Statements

PARIS--(BUSINESS WIRE)--Regulatory News:

Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) (the “Company”) announces the postponement of the publication of its 2024 annual financial report, initially scheduled for April 30, 2025, as well as the finalization and approval of its statutory and consolidated financial statements for 2024.

The Company is facing significant difficulties in accessing the accounting records of its U.S. subsidiary, Valerio Therapeutics Inc. Although the assets related to this subsidiary have been impaired in the Company's statutory accounts and the subsidiary ceased all activities at the end of 2024, this delay in the accounting treatment of Valerio Therapeutics Inc. currently prevents the Company from finalizing its statutory and, consequently, its consolidated financial statements. In 2024, the re-invoicing to the Company of costs from Valerio Therapeutics Inc. (including employee and R&D expenses) remained substantial and therefore has a significant impact on the Company's annual accounts.

As a result, the finalization of the Company’s 2024 statutory and consolidated financial statements and the publication of the 2024 annual financial report will not occur before the end of July 2025. The approval of the 2024 annual financial statements will take place in September 2025.

The Company's cash position remains low. The Company's main shareholder intends to provide funding for Valerio Therapeutics' ongoing operations through June 2025. In the meantime, the Company is continuing discussions with its stakeholders and is seeking to reach an agreement necessary to secure its financial and cash position through the end of 2025.

For more information, visit www.valeriotx.com.

VALERIO THERAPEUTICS
49 boulevard du Général Martial Valin
75015 Paris70.38.33.99

Société Anonyme à Conseil d’Administration au capital de 21 610 998,20 euros
Siège social: 49 boulevard du Général Martial Valin, 75015 Paris

Contacts

Valerio Therapeutics
Relations avec les investisseurs :
ir@valeriotx.com | +33 (0) 1 70 38 33 99 »

Valerio Therapeutics S.A.

BOURSE:ALVIO
Release Versions
EnglishFrench

Contacts

Valerio Therapeutics
Relations avec les investisseurs :
ir@valeriotx.com | +33 (0) 1 70 38 33 99 »

More News From Valerio Therapeutics S.A.

VALERIO THERAPEUTICS: List of the Board Members Positions Held in Other Companies as of March 19, 2025

PARIS--(BUSINESS WIRE)--Regulatory News: VALERIO THERAPEUTICS (Paris:ALVIO):  Name of Director Other offices and functions   Julien MIARA Chief Executive Officer and Director   Managing Director at Invus Director of Sensorion Director of Versity   Jacques MALLET Director and Chairman of the Board   Chairman of Gamma-X Corporate Advisory Director of Technoflex Director of the Fournier Majoie Foundation   FINANCIERE DE LA MONTAGNE, represented by Nicolas TREBOUTA Director   Manager of SARL Financ...

Valerio Therapeutics: Report of the Board of Directors

PARIS--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (Paris:ALVIO): Ladies and Gentlemen, We have convened this General Meeting in order to submit for your approval decisions which fall within the remit of both the Ordinary and Extraordinary General Meetings. You are therefore asked to vote on the following agenda: Agenda for the Ordinary General Meeting First resolution: Dismissal of a member of the Board of Directors (Shefali Agarwal) Second resolution: Ratification of the co-optatio...

Valerio Therapeutics Announces the Termination of the Liquidity Contract Entered Into on 29 October 2018 With KEPLER CHEUVREUX

PARIS--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) (the ‘Company’) announces that it has terminated the liquidity agreement entered into on 29 October 2018 with KEPLER CHEUVREUX (the ‘Agreement’). The termination was effective on 19 February 2025. The termination of the Agreement was decided as part of the savings made by the Company given its cash position. The Company does not intend to enter into another liquidity contract at this stage. It shou...
Back to Newsroom